Towa Pharmaceutical Co., Ltd. (TYO:4553)
Japan · Delayed Price · Currency is JPY 3,345.00
-35.00 (-1.04%)
Nov 13, 2026, 3:30 PM JST
Towa Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 285,488 | 273,710 | 259,594 | 227,934 | 208,859 | 165,615 | |
Revenue Growth | 7.06% | 5.44% | 13.89% | 9.13% | 26.11% | 6.92% |
Cost of Revenue | 182,145 | 174,606 | 164,865 | 146,551 | 136,145 | 95,429 |
Gross Profit | 103,343 | 99,104 | 94,729 | 81,383 | 72,714 | 70,186 |
Selling, General & Admin | 59,984 | 58,047 | 54,954 | 50,405 | 51,825 | 39,381 |
Research & Development | 17,943 | 17,943 | 16,212 | 13,242 | 15,265 | 11,488 |
Operating Expenses | 77,938 | 76,001 | 71,486 | 63,735 | 67,199 | 51,648 |
Operating Income | 25,405 | 23,103 | 23,243 | 17,648 | 5,515 | 18,538 |
Interest Expense | -2,448 | -2,261 | -1,627 | -947 | -635 | -230 |
Interest & Investment Income | 334 | 325 | 232 | 106 | 25 | 14 |
Currency Exchange Gain (Loss) | 882 | 807 | 1,992 | 1,593 | 1,181 | 795 |
Other Non Operating Income (Expenses) | 545 | 720 | 1,051 | 527 | 905 | 725 |
EBT Excluding Unusual Items | 24,718 | 22,694 | 24,891 | 18,927 | 6,991 | 19,842 |
Gain (Loss) on Sale of Investments | -77 | -77 | -38 | -222 | -20 | -563 |
Gain (Loss) on Sale of Assets | -259 | -108 | 230 | 225 | -46 | 96 |
Asset Writedown | -13,255 | -9,345 | 1,247 | 5,550 | -2,282 | 2,896 |
Other Unusual Items | - | - | -1 | -21 | -38 | -26 |
Pretax Income | 11,127 | 13,164 | 26,329 | 24,459 | 4,605 | 22,245 |
Income Tax Expense | 7,225 | 7,914 | 7,343 | 8,286 | 2,404 | 6,331 |
Net Income | 3,902 | 5,250 | 18,986 | 16,173 | 2,201 | 15,914 |
Net Income to Common | 3,902 | 5,250 | 18,986 | 16,173 | 2,201 | 15,914 |
Net Income Growth | -81.10% | -72.35% | 17.39% | 634.80% | -86.17% | 14.01% |
Shares Outstanding (Basic) | 49 | 49 | 49 | 49 | 49 | 49 |
Shares Outstanding (Diluted) | 49 | 49 | 49 | 49 | 49 | 50 |
Shares Change | 0.00% | 0.01% | 0.01% | -0.00% | -2.19% | -1.86% |
EPS (Basic) | 79.26 | 106.65 | 385.70 | 328.58 | 44.72 | 323.35 |
EPS (Diluted) | 79.26 | 106.65 | 385.70 | 328.58 | 44.72 | 316.19 |
EPS Growth | -81.10% | -72.35% | 17.38% | 634.82% | -85.86% | 16.28% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 10,869 | 8,152 | -5,335 | -29,639 | -26,187 | 10,989 |
Free Cash Flow Per Share | 220.79 | 165.60 | -108.38 | -602.17 | -532.02 | 218.36 |
Dividend Per Share | 40.000 | 80.000 | 70.000 | 60.000 | 60.000 | 57.000 |
Dividend Growth | -50.00% | 14.29% | 16.67% | 0% | 5.26% | 29.54% |
Gross Margin | 36.20% | 36.21% | 36.49% | 35.70% | 34.82% | 42.38% |
Operating Margin | 8.90% | 8.44% | 8.95% | 7.74% | 2.64% | 11.19% |
Profit Margin | 1.37% | 1.92% | 7.31% | 7.09% | 1.05% | 9.61% |
Free Cash Flow Margin | 3.81% | 2.98% | -2.05% | -13.00% | -12.54% | 6.64% |
EBITDA | 47,692 | 45,940 | 43,342 | 35,536 | 24,924 | 29,492 |
EBITDA Margin | 16.71% | 16.78% | 16.70% | 15.59% | 11.93% | 17.81% |
D&A For EBITDA | 22,287 | 22,837 | 20,099 | 17,888 | 19,409 | 10,954 |
EBIT | 25,405 | 23,103 | 23,243 | 17,648 | 5,515 | 18,538 |
EBIT Margin | 8.90% | 8.44% | 8.95% | 7.74% | 2.64% | 11.19% |
Effective Tax Rate | 64.93% | 60.12% | 27.89% | 33.88% | 52.20% | 28.46% |